Twist Bioscience Supports the Engineering Biology Research Consortium as it Publishes Statement of Ethics
May 13 2021 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced its support of the
Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology
Research. A companion paper, titled “Guiding ethical principles in engineering biology
research,” to contextualize the purpose and principles
behind the Statement has also now been published in ACS Synthetic
Biology.
Progress in the field of engineering biology has already had a
major impact in medicine, food and agriculture, environmental
sustainability, and bioindustrial manufacturing. In the U.S. alone
in 2016, the most recent data available, engineering biology
accounted for 5.1%i of gross domestic product, as discussed in
“Next Steps to Grow the Bioeconomy”ii
published in Health Security. As with many other rapidly growing
and highly impactful technologies, the long-term implications of
this innovative research require forward-thinking guidelines and
ethical frameworks to support responsible use. The EBRC Statement
urges scientists to consider several guiding principles, including
developing products or processes that benefit people, society, or
the environment, and be aware and mindful of the ethical and
societal consequences at each stage of their research.
“The goal of this Statement of Ethics from EBRC is to facilitate
ongoing reflection and collaboration amongst our peers, the general
scientific community, policymakers, and other stakeholders to
support ethical processes and outcomes in engineering biology
innovation and development,” said James Diggans, Ph.D.,
distinguished scientist, bioinformatics and biosecurity at Twist
Bioscience and member of the EBRC Security Working Group.
“At Twist, we respect and understand the incredible power of our
synthetic DNA technologies and, as such, pursue opportunities to
further our biosecurity and ethical practices,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We remain
at the forefront of biosecurity screening and security research,
enabling our customers to succeed in improving health and
sustainability while actively engaging with external experts to
ensure we continue to anticipate and address potential threats. The
EBRC Statement of Ethics helps to provide additional guidance to
our community, which we welcome and support.”
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of a significant customer; risks of third party
claims alleging infringement of patents and proprietary rights or
seeking to invalidate Twist Bioscience’s patents or proprietary
rights; and the risk that Twist Bioscience’s proprietary rights may
be insufficient to protect its technologies. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s
business in general, see Twist Bioscience’s risk factors set forth
in Twist Bioscience’s Quarterly Report Form 10-Q filed with the
Securities and Exchange Commission on May 7, 2021 and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Twist
Bioscience specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
i The NAS study is Safeguarding the Bioeconomy, c.f https://www.nap.edu/catalog/25525/safeguarding-the-bioeconomy
ii Smith E, Diggans J. Next Steps to Grow the Bioeconomy. Health
Secur. 2020 Jul/Aug;18(4):297-302. doi: 10.1089/hs.2020.0012. PMID:
32816592.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210513005205/en/
Twist Bioscience: Angela Bitting 925-202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2024 to Oct 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Oct 2023 to Oct 2024